title: Regulatory authorities and orthopaedic clinical trials on expanded mesenchymal stem cells.
abstract: Skeletal injuries requiring bone augmentation techniques are increasing in the context of avoiding or treating difficult cases with bone defects, bone healing problems, and bone regeneration limitations. Musculoskeletal severe trauma, osteoporosis-related fractures, and conditions where bone defect, bone collapse or insufficient bone regeneration occur are prone to disability and serious complications. Bone cell therapy has emerged as a promising technique to augment and promote bone regeneration. Interest in the orthopaedic community is considerable, although many aspects related to the research of this technique in specific indications may be insufficiently recognised by many orthopaedic surgeons. Clinical trials are the ultimate research in real patients that may confirm or refute the value of this new therapy. However, before launching the required trials in bone cell therapy towards bone regeneration, preclinical data is needed with the cell product to be implanted in patients to ensure safety and efficacy. These preclinical studies support the end-points that need to be evaluated in clinical trials. Orthopaedic surgeons are the ultimate players that, through their research, would confirm in clinical trials the benefit of bone cell therapies. To further foster this research, the pathway to eventually obtain authorisation from the National Competent Authorities and Research Ethics Committees under the European regulation is reviewed, and the experience of the REBORNE European project offers information and important clues about the current Voluntary Harmonization Procedure and other opportunities that need to be considered by surgeons and researchers on the topic.
authors.affiliation: Department of Orthopaedic Surgery and Traumatology, Hospital La Paz and Universidad Autónoma de Madrid, Madrid, Spain, egomezbarrena@gmail.com.
authors.forename: Enrique
authors.initials: E
authors.lastname: Gómez-Barrena
authors.forename: Cristina Avendaño
authors.initials: CA
authors.lastname: Solá
authors.forename: Carmen Painatescu
authors.initials: CP
authors.lastname: Bunu
mesh_terms: D001847:Bone Diseases / Q000628:therapy*; D001861:Bone Regeneration; D064987:Cell- and Tissue-Based Therapy / Q000379:methods*; D002986:Clinical Trials as Topic / Q000941:ethics* / Q000331:legislation & jurisprudence*; D005060:Europe; D006801:Humans; D045164:Mesenchymal Stem Cell Transplantation; D059630:Mesenchymal Stem Cells; D009985:Orthopedics / Q000379:methods*
references.citation: Acta Orthop Scand. 1998 Jun;69(3):219-20
references.pmid: 9703390
references.citation: World Health Organ Tech Rep Ser. 2003;919:i-x, 1-218, back cover
references.pmid: 14679827
references.citation: J Cell Mol Med. 2011 Jun;15(6):1266-86
references.pmid: 21251219
references.citation: Mol Ther. 2012 Mar;20(3):479-82
references.pmid: 22378030
references.citation: Clin Orthop Relat Res. 2008 Oct;466(10):2306-16
references.pmid: 18679760
references.citation: Int J Artif Organs. 2009 Nov;32(11):811-20
references.pmid: 20020413
references.citation: Lancet. 2012 Dec 15;380(9859):2129-43
references.pmid: 23245605
references.citation: Bone. 2013 Apr;53(2):430-6
references.pmid: 23274347
references.citation: Osteoporos Int. 2000;11(8):669-74
references.pmid: 11095169
references.citation: Ann N Y Acad Sci. 2009 Sep;1176:118-23
references.pmid: 19796239
references.citation: BMJ Open. 2013 Feb 08;3(2):
references.pmid: 23396560
references.citation: Cytotherapy. 2006;8(4):315-7
references.pmid: 16923606
references.citation: Intensive Care Med. 2009 Sep;35(9):1636-40
references.pmid: 19543709
references.citation: Artif Organs. 2010 Mar;34(3):215-22
references.pmid: 19392880